ClearPoint Neuro, Inc.

ClearPoint Neuro, Inc. develops and commercializes image-guided neurosurgery platforms used for minimally invasive procedures in the brain. Its business combines capital equipment and disposable products for the ClearPoint system with consulting and service revenue tied to biologics and drug delivery programs that aim to deliver therapies directly to targeted brain tissue.

−63,2 %

61,4 %

−69,1 %

+17,8 %

5.91

5.13

— ClearPoint Neuro, Inc.
	%
Neurosurgery navigation and therapy products	55% Capital and disposable products used for image-guided brain procedures, including the ClearPoint platform and related navigation systems.
Biologics and drug delivery services	40% Consulting, protocol design, and execution support for customers developing gene, cell, and other brain-delivery therapies.
Laser therapy and adjunct commercialization products	5% Therapy-related offerings such as the Prism laser system and newer product launches that expand the platform's clinical use cases.

ClearPoint sells to hospitals and neurosurgeons for clinical procedures, while its biologics and drug delivery business...

Clinical neurosurgery usersprimary
Hospitals and surgeons buy ClearPoint navigation and therapy products for minimally invasive brain procedures.
Biologics and drug delivery partnersprimary
Pharma and biotech customers buy consulting and workflow support to develop therapies delivered into the brain.
Academic research institutionssecondary
Universities and research centers use the platform for preclinical and translational neuroscience work.
Contract research organizationssecondary
CROs use ClearPoint-related services to support customer-sponsored studies and trial execution.

The company is headquartered in the United States and received FDA clearances for its core products there, making the U...

•United States is the core commercial and regulatory market
•FDA clearances support U.S. product sales and adoption
•CE marking enables sales in Europe for selected products
•International growth depends on regulatory approvals and clinical uptake
•Brain-delivery programs face region-specific trial and approval pathways

ClearPoint is focused on expanding its commercial neurosurgery platform while building a larger biologics and drug...

Grow biologics and drug delivery partnershipsmedium-term

This is management's largest stated growth opportunity and can create recurring service and product demand.

Expand ClearPoint platform commercializationshort-term

Recurring product sales from the installed base help stabilize revenue and support operating leverage.

Broaden therapy applicationsmedium-term

New indications and products increase the number of procedures and addressable customers.

The business depends on clinical and regulatory success in highly uncertain brain-therapy programs, so delays or...

high

Regulatory delay or failure for cell and gene therapies

A large part of growth depends on customers' therapies reaching approval and commercialization.

Scope: Biologics and drug delivery business
Materiality: high

high

Continued operating losses and financing dependence

The company has not achieved profitability and has historically funded operations with equity and debt.

Scope: Enterprise-wide
Materiality: high

medium

Merger integration risk

The planned IRRAS transaction may create integration costs, employee retention issues, and liability surprises.

Scope: Post-merger operations
Materiality: high

medium

Commercial adoption risk

New neurosurgical products require surgeon training, workflow integration, and clinical acceptance.

Scope: ClearPoint platform
Materiality: medium

Revenue recognition by product vs service line

Product sales are mostly ClearPoint-related; service revenue is tied to biologics programs

Project-based and partner-driven timing

Can make revenue and operating leverage difficult to forecast

Merger-related valuation and liabilities

Could affect goodwill, intangible assets, and future impairment risk

ClearPoint Neuro, Inc.

Regulatory delay or failure for cell and gene therapies

Continued operating losses and financing dependence

Merger integration risk

Commercial adoption risk

NEUROONE MEDICAL TECHNOLOGIES Corp

Neuronetics, Inc.

Neuraxis, INC

JUPITER NEUROSCIENCES, INC.

NEUROCRINE BIOSCIENCES INC

Cleartronic, Inc.